Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICE: VEGF-targeted Fluorescence Endoscopy
NCT02129933Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab-IRDye800CW in esophageal cancer and Barrett's esophagus, sponsored by University Medical Center Groningen. Primary endpoint: Near-Infrared Fluorescent Signal In Vivo (Prior to EMR) at 1 day. Started Apr 2014; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
esophageal cancerBarrett's esophagus
Beyond the preview
Go deeper on NCT02129933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129933.